Oramed Pharmaceuticals (NASDAQ: ORMP) revenue
Oramed Pharmaceuticals reported revenue of $2.0m for fiscal 2025; in fiscal 2023 it was $1.3m. Since fiscal 2016 its revenue has grown by 212.0%, an average growth of 13.5% a year.
Oramed Pharmaceuticals's best year of the last 9 was fiscal 2020. The biggest drop was in fiscal 2023, −50.4%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $2.0m | — | −$15.1m | −754.4% |
| 2023 | $1.3m | −50.4% | −$15.8m | −1,176.8% |
| 2022 | $2.7m | — | −$40.6m | −1,502.0% |
| 2021 | $2.7m | −0.3% | −$24.2m | −896.2% |
| 2020 | $2.7m | +0.3% | −$11.8m | −433.8% |
| 2019 | $2.7m | +10.4% | −$14.6m | −541.3% |
| 2018 | $2.4m | −0.3% | −$13.5m | −552.3% |
| 2017 | $2.5m | +283.2% | −$10.8m | −438.6% |
| 2016 | $0.6m | — | −$10.0m | −1,561.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Oramed Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Oramed Pharmaceuticals ranks 393rd of the 422 US health care companies with a page on Celsmar.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 391st | Cartesian Therapeutics | $2.8m | −92.8% |
| 392nd | Allogene Therapeutics | $2.6m | 2,500.0% |
| 393rd | Oramed Pharmaceuticals | $2.0m | — |
| 394th | Celldex Therapeutics | $1.5m | −78.0% |
| 395th | Inhibrx Biosciences | $1.3m | 550.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Oramed Pharmaceuticals
- How much revenue did Oramed Pharmaceuticals make in fiscal 2025?
- Oramed Pharmaceuticals reported revenue of $2.0m for fiscal 2025, compared with $1.3m in fiscal 2023.
- How much has the revenue of Oramed Pharmaceuticals grown?
- Between fiscal 2016 and fiscal 2025 it went from $0.6m to $2.0m: 212.0% more, an average growth of 13.5% a year.
- What was the best year for revenue at Oramed Pharmaceuticals?
- Of its last 9 fiscal years, fiscal 2020, with $2.7m.
- Where does Oramed Pharmaceuticals rank in its sector by revenue?
- It ranks 393rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Oramed Pharmaceuticals come from?
- From the annual report (Form 10-K) that Oramed Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Oramed Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Oramed Pharmaceuticals: the Oramed Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.